Asian Journal of Medical Principles and Clinical Practice

Lassa Fever Resurgence: The Nigeria Perspective

Christopher Chukwu Ifunanya

Department of Public Health, School of Health Sciences, Birmingham City University, United Kingdom.

Rhoda Nwalozie *

Department of Medical Laboratory Science, Rivers State University, Port Harcourt, Nigeria.

Joel Burabari Konne

School of Public Health, University of Port Harcourt, Rivers State, Nigeria.

Ibiobelem Ann Jackreece

Department of Haematology, Blood Transfusion and Immunology, University of Port Harcourt, Nigeria.

*Author to whom correspondence should be addressed.

---

Abstract

Lassa fever (LF) is one of the chronic, zoonotic, viral haemorrhagic diseases that is caused Lassa virus, belonging to the family of arenaviruses, a member of the family Arenaviridaer. The Lassa virus was described in the year 1950s, but was not named until 1969. The first case of Lassa fever was recorded in Nigeria, there have been several outbreaks across other West African nations such as Sierra Leone, Togo, Benin Republic, Guinea, Liberia, Ghana, and Mali. Of all viral hemorrhagic fevers (VHF) exported to the Europe and America, Lassa fever ranks the highest. In light of the current resurgence of Lassa fever in Nigeria, Lassa fever cases in the country has risen to 857, with 167 deaths recorded from the disease between January and July 2022. Ondo has 30% of the confirmed cases, followed by Edo with 26% and Bauchi with 14%. Lassa fever comprising of Lassa, Junin, Lujo, Guanarito, and Machupo. The Filoviridae comprising of Ebola and Marburg viruses, and the Bunyaviridae is made up of Rify Vaey Fever and Crimean Congo haemorrhagic fever. Animal to human transmission is caused by contact with droplets from Natal Multimammate rat or the African rat (Mastomys natalensis), while human-to-human transmission occurs through contact with infected fluid from an infected person. The incubation period of Lassa fever ranges between 6–21 days and is accompanied with the clinical symptoms such as gradual slight fever, malaise and general weakness, followed by serious symptoms like abdominal, chest, and muscle pains, cough, headache, sore throat, nausea, shock, swelling of the face, diarrhea, and frequent vomiting. More severe cases result to bleeding and eventually death. It can be prevented by avoiding areas endemic with the host animal, observing proper hygiene, and the use of proper personal protective equipment for health workers. No specific treatment is available for Lassa fever infection, although ribavirin has been suggested to be effective when administered at the onset of infection.

Keywords: Lassa fever, haemorrhagic, disease, arenaviridae, Mastomys natalensis, ribavirin

---

---

---

References

World Health Organization (W.H.O1). Lassa Fever; 2017.

Available:https://www.who.int/en/news-room/fact-sheets/detail/lassa-fever

Accessed August 26, 2022

Centers for Diseases Control and Prevention (CDC). Lassa Fever; 2022.

Available:https://www.cdc.gov/vhf/lassa/index.html

Accessed August 26, 2022

Akpede GO, Asogun DA, Okogbenin SA, Okokhere PO. Lassa fever outbreaks in Nigeria. Expert Rev Anti Infect Ther. 2018;16(9):663-666.

DOI:10.1080/14787210.2018.1512856. Epub 2018 Aug 24. PMID: 30111178.

Ogbu O, Ajuluchukwu E, Uneke CJ. Lassa fever in West African sub-region: an overview. J Vector Borne Dis. 2007;4(1):1-11. PMID: 17378212.

European Centre for Disease Prevention and Control (2016) Lassa fever in Nigeria, Benin, Togo, Germany and USA−23 March 2016; 2016.

Available:https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2017.22.39.17-00088?crawler=true

Kofman A, Choi MJ, Rollin PE. Lassa Fever in Travelers from West Africa, 1969-2016. Emerg Infect Dis. 2019;25(2):245-248.

DOI:10.3201/eid2502.180836. PMID: 30666924; PMCID: PMC6346466.

Choi MJ, Worku S, Knust B, Vang A, Lynfield R, Mount MR, Objio T, Brown S, Griffith J, Hulbert D, Lippold S, Ervin E, Ströher U, Holzbauer S, Slattery W, Washburn, F, Harper J, Koeck M, Uher C, Rollin P, Nichol S, Else R, DeVries A. A case of lassa fever diagnosed at a community Hospital-Minnesota 2014. Open Forum Infect Dis. 2018;5(7) ofy131.

DOI:10.1093/ofid/ofy131.

PMID: 30035149; PMCID: PMC6049013.

African CDC (2022). Lassa fever.

Available:https://africacdc.org/disease/lassa-fever/

Accessed August 30, 2022

Goeijenbier M, Wagenaar J, Goris M, Martina B, Henttonen H, Vaheri A, Reusken, C, Hartskeerl R, Osterhaus A, Van Gorp E. Critical Reviews in Microbiology. 2012;39(1):26–42.

DOI:10.3109/1040841X.2012.686481. PMID 22670688. S2CID 31217913

David G, Barbara K, Eric JD. What pediatricians should know about lassa virus. JAMA Pediatrics. 2018;172(5):407–408.

DOI:10.1001/jamapediatrics.2017.5223. PMC 5970952. PMID 29507948.

Richmond JK, Baglole DJ. Lassa fever: Epidemiology, clinical features, and social consequences. BMJ. 2003;327(7426): 1271–1275.

DOI:10.1136/bmj.327.7426.1271. PMC 286250. PMID 14644972. Retrieved from the original: August 30, 2022

Maxmen A. Deadly Lassa-fever outbreak tests Nigeria's revamped health agency. Nature. 2018;555 (7697):421–422.

Bibcode:2018Natur.555..421M.

DOI:10.1038/d41586-018-03171-y.

PMID 29565399.

Beaubien J. Nigeria faces mystifying spike in deadly lassa fever. NPR; 2018.

Available:https://www.npr.org/sections/goatsandsoda/2018/03/19/587603462/nigeria-faces-mystiifying-spike-in-deadly-lassa-fever Accessed September 5, 2022

W.H.O.2 Lassa Fever – Nigeria: Emergencies, response; 2018.

Available:https://web.archive.org/web/20180301141952/, http://www.who.int/csr/don/01-march-2018-lassa-fever-nigeria/en/

Retrieved September 5, 2022.

W.H.O.3. Lassa Fever – Nigeria; 2022.

Available:https://www.who.int/emergencies/disease-outbreak-news/item/lassa-fever---nigeria Accessed September 5, 2022

Premium Times NG. Nigeria’s Lassa fever deaths hit 164 – NCDC; 2022.

Available:https://www.premiumtimesng.com/news/headlines/545927-nigerias-lassa-fever-deaths-hit-164-ncdc.html Accessed September 6, 2022

Reliefweb. NCDC Lassa fever Situation Report Epi Week 24: 13 - 19 June, 2022.

Available:https://reliefweb.int/report/nigeria/ncdc-lassa-fever-situation-report-epi-week-24-13-19-june-2022 Retrieved September 6, 2022

Viral Hemorrhagic Fever Consortium (VHFC). Lassa; 2022.

Available:https://vhfc.org/diseases/lassa/

Retrieved September 7, 2022

Peterson AT, Moses LM, Bausch DG. mapping transmission risk of lassa fever in West Africa: The importance of quality control, sampling bias, and error weighting. PLOS ONE. 2014;9(8): e100711. Bibcode:2014PLoSO...9j0711P.

DOI:10.1371/journal.pone.0100711. ISSN 1932-6203. PMC 4126660. PMID 25105746.

Goeijenbier M, Wagenaar J, Goris M, Martina B, Henttonen H, Vaheri A, Reusken C, Hartskeerl R, Osterhaus A. Rodent-borne hemorrhagic fevers: under-recognized, widely spread and preventable – epidemiology, diagnostics and treatment. Critical Reviews in Microbiology. 2013;39 (1): 26–42.

DOI:10.3109/1040841X.2012.686481. ISSN 1040-841X. PMID 22670688.

Richmond JK, Baglole DJ. Lassa fever: Epidemiology, clinical features, and social consequences. BMJ. 2003;327(7426): 1271–1275.

DOI:10.1136/bmj.327.7426.1271. PMC 286250. PMID 14644972.

Evan S, Neha P. What is Lassa Fever?; 2022.

Available:https://www.webmd.com/a-to-z-guides/lassa-fever-overview

Accessed September 7, 2022

WHO4. Lassa Fever; 2022.

Available:https://www.who.int/health-topics/lassa-fever#tab=tab_1

Accessed September 7, 2022

CDC. Lassa – Transmission; 2014.

Available:https://www.cdc.gov/vhf/lassa/transmission/index.html

Retrieved September 7, 2022

Sandra GG, Charles PD. Lassa Fever. MedicineNet; 2022.

Available:https://www.medicinenet.com/lassa_fever/article.htm

Accessed September 8, 2022

Mazzola LT, Kelly-Cirino C. Diagnostics for Lassa fever virus: a genetically diverse pathogen found in low-resource settings. BMJ Global Health. 2019;4:e001116.

Branco LM, Grove JN, Boisen ML, et al. Emerging trends in Lassa fever: redefining the role of immunoglobulin M and inflammation in diagnosing acute infection. Virol J. 2011;8:478.

DOI:10.1186/1743-422X-8-478

Yun NE, Walker DH. Pathogenesis of Lassa fever. Viruses. 2012 Oct 9; 4(10):2031-48.

DOI: 10.3390/v4102031. PMID: 23202452; PMCID: PMC3497040.

Baize S, Marianneau P, Loth P, et al. Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys. J Virol. 2009;83: 5890–903.

Doi:10.1128/Jvi.01948-08

Fischer WA, Wohl DA. Moving Lassa fever research and care into the 21st century. J Infect Dis. 2017;215:1779–81.

DOI:10.1093/INFDIS/JIX206

Sogoba N, Rosenke K, Adjemian J, et al. Lassa virus seroprevalence in sibirilia commune, Bougouni District, Southern Mali. Emerg Infect Dis. 2016;22:657– 63.

DOI:10.3201/EID2204.151814

Boisen ML, Hartnett JN, Shaffer JG, et al. Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever. Sci Rep. 2018;8: 5939.

DOI:10.1038/S41598-018-24246-W

Boisen ML, Cross RW, Hartnett JN, et al. Field Validation of the ReEBOV antigen rapid test for point-of-care diagnosis of ebola virus infection. J Infect Dis. 2016;214(suppl 3):S203–9.

DOI:10.1093/INFDIS/JIW261

Boisen ML, Oottamasathien D, Jones AB, et al. Development of prototype filovirus recombinant antigen immunoassays. J Infect Dis. 2015;212(Suppl 2):S359–67.

DOI:10.1093/INFDIS/JIV353

Eberhardt KA, Mischlinger J, Jordan S, Groger M, Günther S, Ramharter M. Ribavirin for the treatment of Lassa fever: A systematic review and meta-analysis. International Journal of Infectious Diseases. 2019;87:15–20.

DOI:10.1016/j.ijid.2019.07.015. PMID 31357056.

Virus Pathogen database and Analysis Resource (ViPR). Lassa Virus; 2022.

Available:https://www.viprbrc.org/brc/home.spg?decorator=arena_lassa

Accessed September 10, 2022

Kelly JD, Barrie MB, Ross RA, Temple BA, Moses LM, Bausch DG. Housing equity for health equity: a rights-based approach to the control of Lassa fever in post-war Sierra Leone. BMC Int Health Hum Rights.2013;2:13:2.

DOI: 10.1186/1472-698X-13-2.

PMID: 23282054; PMCID: PMC3562201.